Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP) has announced a partnership with TARA Mind, in coordination with Veterans Exploring Treatment Solutions (VETS), to support clinical trial recruitment for its PARADIGM HLP003 Phase 3 program targeting major depressive disorder. The collaboration aims to expand mental health awareness within the veteran community while leveraging the networks of TARA Mind and VETS to enhance veteran engagement. This initiative aligns with the April 18, 2026 Executive Order on accelerating treatments for serious mental illness, as Helus advances its FDA Breakthrough Therapy-designated HLP003 program and broader pipeline of novel serotonergic agonists.
The Phase 3 program, known as PARADIGM, evaluates HLP003 as an adjunctive treatment for major depressive disorder. Helus Pharma previously received Breakthrough Therapy Designation from the U.S. Food and Drug Administration for HLP003, underscoring its potential to address significant unmet needs in mental health. The partnership with TARA Mind and VETS is expected to facilitate recruitment by connecting with veterans who may benefit from the investigational therapy. The company is also developing HLP004, a proprietary novel serotonergic agonist in Phase 2 for generalized anxiety disorder, and maintains an extensive research portfolio of investigational NSAs.
Helus Pharma, the commercial operating name of Cybin Inc., is a clinical-stage pharmaceutical company focused on developing proprietary synthetic molecules designed to activate serotonin pathways that promote neuroplasticity. The company aims to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions. With class-leading data, Helus Pharma seeks to improve the treatment landscape through durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland.
For further details on the partnership and the PARADIGM Phase 3 program, the full press release is available at https://ibn.fm/o9dCH. More information about Helus Pharma can be found at www.helus.com, and the latest news and updates relating to HELP are available in the company’s newsroom at https://ibn.fm/HELP.
